Pfizer recalls migraine tablets, cites contamination risk

Pfizer is recalling two lots of Relpax, tablets to treat migraines, due to bacterial contamination concerns.

The affected lots, AR5407 and CD4565, were tested and potentially contain Pseudomonas and Burkholderia bacteria.

"Individuals who consume oral products contaminated with microorganisms are at risk of bacterial dissemination from the gut to the bloodstream potentially resulting in serious, life- threatening infections," the recall notice reads. 

Pfizer has notified customers via a recall letter and plans to arrange returns of the affected products. 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars

>